descriptionPublicationkeyboard_double_arrow_right Article 01 Apr 2013 English Publisher:Ovid Technologies (Wolters Kluwer Health)Journal:American Journal of Gastroenterology, volume 108, pages 620-621 (issn: 0002-9270,

Authors: Jeanne, Tung; Sunanda, Kane; Felicity T, Enders; Elysia N, Jeavons;

doi: 10.1038/ajg.2013.31

pmid: 23552314

Hepatitis B Vaccine in IBD

- Summary
- Subjects
- Metrics

Abstract

To the Editor: We read with great interest the article by Gisbert et al. (1), which investigated giving vaccine against hepatitis B virus (HBV) at an accelerated, double dosage in patients with inflammatory bowel disease (IBD). The overall seroconversion rate was low, particularly in those receiving biological therapy. Immunosuppressants, however, did not affect vaccine efficacy (1).

Related Organizations

Mayo Clinic
United States

Keywords

Male, Tumor Necrosis Factor-alpha, Humans, Female, Hepatitis B Vaccines, Hepatitis B, Inflammatory Bowel Diseases, Immunosuppressive Agents

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	2
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average